Because CD73 upregulation in tumors leads to local immunosuppression, oleclumab, an anti-CD73 human IgG1λ monoclonal antibody, was assessed in combination with durvalumab versus oleclumab alone in a cohort of patients with MSS cancers, of which 21.9% had mCRC. This evidence concerns the gene NT5E and cancer.